The multiplex assays market is segmented on
the basis of product
& services, type, technology, application, end user, and region. By product and service, the
multiplex assays market is segmented into instruments, consumables, and
software & services. In 2018, the consumables segment is expected to
account for the largest share of the market; it is also the fastest-growing
segment of the multiplex assays market. This can be attributed to the recurring
purchase of assays and reagents for increasing research applications.
Download FREE Brochure @
On
the basis of type, the global multiplex assays market is divided into protein
multiplex assays, nucleic acid multiplex assays, and cell-based multiplex
assays. In 2018, the protein multiplex assays segment is expected to grow at
fastest CAGR in the global multiplex assays market. This high growth can be
attributed to the increasing focus on proteomics studies for biomarker research
and clinical diagnostics.
On
the basis of technology, the global multiplex assays market is divided into
flow cytometry, multiplex RT PCR, luminescence, fluorescence detection, and
other technologies. In 2018, the flow cytometry segment is expected to grow at the
highest CAGR in the global multiplex assays market. The high growth can be
attributed to the wide applications of flow cytometry in detection &
measurement of protein expression, RNA, cell health status (cell viability
& toxicity), and characterization & identification of various cell
types.
On
the basis of application, the global multiplex assays market is divided into
research & development and clinical diagnostics. In 2018, the clinical
diagnostics segment is expected to grow at the highest CAGR in the global
multiplex assays market. This high growth can be attributed to increasing
disease prevalence and adoption of multiplex assays in diagnosis.
On
the basis of end user, the global multiplex assays market is divided into
pharmaceutical and biotechnology companies, hospitals & academic research
institutes, reference laboratories, and other end users. In 2018, the
pharmaceutical and biotechnology companies segment is expected to grow at the
highest CAGR in the global multiplex assays market.
This high growth can be attributed to the increased
adoption of multiplex assays in drug discovery & development by
pharmaceuticals and the growing focus of biotechnology companies on developing
biosimilars and monoclonal antibodies.
The
APAC market is projected to register the highest growth rate during the
forecast period primarily due to its pharmaceutical market, which is growing at
the fastest pace in the world, the availability of a large number of qualified
researchers, and increasing prevalence of cancer and infectious diseases.
To Know More @
No comments:
Post a Comment